Cointime

Nohla Therapeutics

company

About

Nohla Therapeutics is a developing an shelf alternative to bone marrow transplants

  • 11 - 50

Highlights

Total Funding Amount
$99.50M
Funding Rounds
3
Investors
2

Details

Last Funding Type
Series A
Last Funding Money Raised
$43.50M
Industries
Biotechnology,Health Diagnostics,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
11 - 50
Operating Status
Close

Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$99.50M
Nohla Therapeutics has raised a total of $99.50M in funding over 2 rounds. Their latest funding was raised on Jul 12, 2018 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 12, 2018 Series B $11M 2 — — Detail
May 15, 2018 Series B $45M 2 — — Detail
Nov 30, 2016 Series A $43.50M 1 ARCH Venture Partners — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Nohla Therapeutics is funded by 2 investors. ARCH Venture Partners and AML Biotech Partners are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners — Series B
AML Biotech Partners — Series B
Cointime
Content
Company